European Journal of Cancer (1965)最新文献_第5页

Treatment of soft tissue sarcomas 软组织肉瘤的治疗

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90255-3

J.S. Abbatucci, N. Boulier, A.M. Mandard, A. Tanguy, J. Wyplosz

{"title":"Treatment of soft tissue sarcomas","authors":"J.S. Abbatucci, N. Boulier, A.M. Mandard, A. Tanguy, J. Wyplosz","doi":"10.1016/0014-2964(81)90255-3","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90255-3","url":null,"abstract":"<div>The results obtained in the treatment of 45 cases of soft tissue sarcomas are presented. All cases were reviewed and classified according to the modern criteria of malignancy. The treatment schedule comprised: (1) Preoperative irradiation: two sessions of 650 cGy in 48 hr—Target volume: whole limb segment; (2) Surgical excision 48 hr later with systematic intraoperative histologic verification, until healthy tissue margins are obtained; (3) Postoperative irradiation 3 weeks later delivering a cumulative total dose of 5000 cGy to the preoperative volume and 6000–7000 cGy to a reduced volume encompassing the surgical region with protection of vascular axes where possible; (4) Chemotherapy: Actinomycin D 0.3 mg/m2 half an hour before the first 5 sessions of post-operative irradiation; (5) Bilateral lung irradiation: 4 sessions of 375 cGy in 7 days to the whole chest. The results were as follows: Local recurrence rate was 12% at 5 years. In 21 cases in whom surgical excision was deemed histologically adequate, no recurrences were seen at 2 years (minimum follow-up). Survival at 5 years was 76%. Deaths were due to metastatic spread, especially to the lungs. These results show an improvement as compared with historical series. New progress should be sought in combining a more aggressive type of chemotherapy for cases with high metastatic risk.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 455-464"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90255-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72069688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Evaluation of intratumoral immunostimulants in the treatment of a transplantable rat mammary carcinoma 肿瘤内免疫刺激剂治疗可移植大鼠乳腺癌的疗效评价

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90248-6

N. Willmott , E.B. Austin , M.V. Pimms , R.W. Baldwin

{"title":"Evaluation of intratumoral immunostimulants in the treatment of a transplantable rat mammary carcinoma","authors":"N. Willmott , E.B. Austin , M.V. Pimms , R.W. Baldwin","doi":"10.1016/0014-2964(81)90248-6","DOIUrl":"10.1016/0014-2964(81)90248-6","url":null,"abstract":"<div>One C. parvum preparation and two BCG (Bacillus Calmette-Guérin) strains have been evaluated for their effects, when injected intratumorally, on established growths of a transplantable rat mammary carcinoma of spontaneous origin. It was found that whilst the anti-tumor effect of intratumoral injection varied from experiment to experiment certain conclusions could be drawn. Thus for maximal effect the injection should be given as early as possible and at a high dose; furthermore, multiple intratumoral injections appeared to offer no advantage over a single injection. It was also apparent that the anti-tumor effect following intratumoral injection of C. parvum or BCG was not improved when the tumor-bearing animals were presensitised to these immunostimulants. Intratumoral C. parvum was also used as an adjunct to surgery in the treatment of metastases; however, in this model it did not improve the effect of surgery alone. It is concluded that under certain defined circumstances intratumoral injection can bring about tumor regression. However, the conditions under which it is effective may render this form of treatment of limited application.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 397-405"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90248-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18320789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and bacillus Calmette-Guerin 使用长春新碱(NSC-67574)、DTIC (NSC-45388)和卡介苗芽孢杆菌治疗转移性恶性黑色素瘤的化学免疫疗法

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90256-5

N. Thatcher , G. Blackledge , M.K. Palmer , D. Crowther

{"title":"Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and bacillus Calmette-Guerin","authors":"N. Thatcher , G. Blackledge , M.K. Palmer , D. Crowther","doi":"10.1016/0014-2964(81)90256-5","DOIUrl":"10.1016/0014-2964(81)90256-5","url":null,"abstract":"<div>Forty-seven patients with stage IV malignant melanoma were treated with pulses of Vincristine and DTIC. Intercalated, monthly BCG was administered by multiple puncture gun. No patient exclusions were made. The response rate was 38%; all complete responders (8.5%) were metastatic to skin and nodes only. The median survival of the responder patient group was 6.7 months (1–21) and 2 months (< 1–47 +) for non-responders. No significant differences were found for response nor survival length between patients grouped according to sex, severity of haematological toxicity, intervals from initial diagnosis to appearance of metastases or to start of therapy. Patients with the higher Karnofsky scores survived longer. No side effects attributable to BCG were noted and no serious haematological toxicity was encountered. Despite a high response rate, survival was disappointing, and represented the presence of metastases in more than one organ system with only a minority (13%) of patients having metastases in ‘favourable’ (skin, node) sites. A full description of metastatic sites and other prognostic features is necessary for future treatment evaluation.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 465-469"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90256-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18320792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support 晚期睾丸癌的大剂量化疗及自体骨髓支持治疗

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90252-8

G. Blijham , G. Spitzer , J. Litam , A.R. Zander , D.S. Verma , L. Vellekoop , M.L. Samuels , K.B. McCredie , K.A. Dicke

{"title":"The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support","authors":"G. Blijham , G. Spitzer , J. Litam , A.R. Zander , D.S. Verma , L. Vellekoop , M.L. Samuels , K.B. McCredie , K.A. Dicke","doi":"10.1016/0014-2964(81)90252-8","DOIUrl":"10.1016/0014-2964(81)90252-8","url":null,"abstract":"<div>Thirteen patients with disseminated nonseminomatous germ cell carcinoma, failing to respond to extensive prior chemotherapy including cis-platinum, were treated with high dose chemotherapy. Cyclophosphamide (4.5g/m2) and epipodophyllotoxin (VP-16) (600 mg/m2) were given followed by autologous bone marrow transplantation. In some cases 1,3 bis (β-chloroethyl)-1-nitrosourea (BCNU), adriamycin or platinum were also administered. Of 10 patients evaluable for response 9 responded; 4 patients achieved a complete remission and 3 a partial remission. Median response duration was 15 weeks (range 4 to 20+ weeks). Four patients died from treatment-related infections; 2 of whom entered the program already with fever and 3 of whom died after hematopoietic recovery. Major toxicities were bacterial and fungal infections. In patients treated with cyclophosphamide and VP-16 only, no fever was seen in 3 out of 9 courses. Granulocyte transfusion was given in only 1 of 9 courses. Neutrophils recovered to greater than 1.5 × 109/liter by day 18–35 (median 23) and platelets greater than 100 × 109/liter by day 16 to 42+ (median 21). Further experience with high dose cyclophosphamide and VP-16 followed by autologous bone marrow transplantation is needed to evaluate its value in the management of patients with disseminated nonseminomatous germ cell tumor failing front line conventional chemotherapy.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 433-441"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90252-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18078497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 53

Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs 局部灌注治疗肢体局部转移性恶性黑色素瘤

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90257-7

H. Martijn, J. Oldhoff, H.Schraffordt Koops

{"title":"Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs","authors":"H. Martijn, J. Oldhoff, H.Schraffordt Koops","doi":"10.1016/0014-2964(81)90257-7","DOIUrl":"10.1016/0014-2964(81)90257-7","url":null,"abstract":"<div>During the period 1964–1977, regional perfusion and wide local excision were used in the treatment of 104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of 3-year and 5-year survival, which was 52% (<math><mtext>52</mtext><mtext>100</mtext></math>) and 38% (<math><mtext>30</mtext><mtext>78</mtext></math>), respectively. The 3-year and 5-year survival rates in 18 patients treated by normothermic perfusion prior to 1969 were 22% (<math><mtext>4</mtext><mtext>18</mtext></math>) and 17% (<math><mtext>3</mtext><mtext>18</mtext></math>), respectively; in 82 patients treated by hyperthermic perfusion after 1969, the 3-year survival was 58.5% (<math><mtext>48</mtext><mtext>82</mtext></math>) and the 5-year survival was 45% (<math><mtext>27</mtext><mtext>60</mtext></math>). The difference between the normothermic and hyperthemic group is significant at the 3-year and 5-year level (P < 0.005 and P < 0.025, respectively). The 5-year survival in those treated by hyperthermic perfusion was 42% in stage II (n = 12) and 46% in stage III (n = 48), the difference not being significant. The male 5-year survival was 36% (<math><mtext>8</mtext><mtext>22</mtext></math>), while the female was 53% (<math><mtext>20</mtext><mtext>38</mtext></math>). The 5-year survival for tumours of the arm and those of the leg was 23% (<math><mtext>3</mtext><mtext>13</mtext></math>) and 51% (<math><mtext>24</mtext><mtext>47</mtext></math>), respectively. No significancy could be demonstrated between these groups. Of the entire group of 100 patients, 35 developed a local recurrence after perfusion; in 11 there was simultaneous general metastazation as well. The recurrence developed within 2 years after perfusion in 27 (77%) patients and 16 (76%) died within 2 years of recurrence.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 471-476"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90257-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18344593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 42

Tumour enzymes and prognosis in human breast cancer 人乳腺癌的肿瘤酶与预后

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90253-X

N. Deshpande , Irene Mitchell , Rosemary Millis

引用次数: 24

Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume t80通过明显减少血浆体积增加小鼠血浆中阿霉素浓度

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90246-2

S.D. Harrison Jr. , A.M. Cusic, S.M. McAfee

{"title":"Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume","authors":"S.D. Harrison Jr. , A.M. Cusic, S.M. McAfee","doi":"10.1016/0014-2964(81)90246-2","DOIUrl":"10.1016/0014-2964(81)90246-2","url":null,"abstract":"<div>Coadministration of Tween 80 enhances the activity of adriamycin against selected experimental tumors in mice. Although some investigators have suggested a direct effect of Tween 80 on tumor cells, we wished to determine whether altered plasma concentrations of adriamycin occurred which might account for the apparent therapeutic synergism. Male CDF1 mice were treated i.p. with 6.7 mg/kg of adriamycin alone or combined with 5000 mg/kg of Tween 80 in physiologic saline. Fluorometric determination of adriamycin equivalents in plasma revealed significantly higher adriamycin concentrations 1 and 2 hr post treatment in mice that had received Tween 80. In three separate experiments, a significant, reversible increase in packed cell volume occurred in the peripheral blood of mice treated i.p. with Tween 80. This increase was maximal at 1–2 hr post treatment. The magnitude of the apparent plasma volume reduction accounted quantitatively for the increase in drug concentration.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 387-389"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90246-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18320787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Hodgkin's disease following infectious mononucleosis 传染性单核细胞增多症后的霍奇金病

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90258-9

U. Jehn , H. Sauer , H. Wolf , W. Wilmanns

引用次数: 7

Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer 雌激素受体，转移部位和复发性乳腺癌的生存率

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90254-1

John F. Stewart , Roger J.B. King , Sheila A. Sexton , Rosemary R. Millis , Robert D. Rubens , John L. Hayward

引用次数: 136

Recent journal contents 最近的日记账内容

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90260-7

引用次数: 0